BBLG
Bone Biologics Corp

3,725
Mkt Cap
$3.97M
Volume
125.00
52W High
$10.74
52W Low
$1.95
PE Ratio
-0.11
BBLG Fundamentals
Price
$2.21
Prev Close
$2.20
Open
$2.20
50D MA
$2.32
Beta
0.64
Avg. Volume
6.01M
EPS (Annual)
-$28.97
P/B
0.56
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the...
Business Wire·1y ago
News Placeholder
More News
News Placeholder
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive...
Business Wire·1y ago
News Placeholder
First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been...
Business Wire·1y ago
News Placeholder
Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update
Bone Biologics Co. (NASDAQ:BBLG Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 31,100...
Ticker Report·2y ago
News Placeholder
Bone Biologics Announces Closing of $2.0 Million Public Offering
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously...
Business Wire·2y ago
News Placeholder
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of...
Business Wire·2y ago
News Placeholder
Bone Biologics Reports Progress With NB1 Clinical Program
Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for...
Business Wire·2y ago
News Placeholder
Bone Biologics files to sell common stock and warrant
Bone Biologics files to sell common stock and warrant...
SeekingAlpha.com: All News·2y ago
News Placeholder
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E...
Business Wire·2y ago
News Placeholder
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Corporation (Bone Biologics or the Company) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The...
Business Wire·2y ago

Latest BBLG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.